News | Renal Denervation | August 23, 2016

Technavio Reports Renal Denervation Devices on the Rise

Prevalence of hypertension, rise of minimally invasive procedures and new technological innovations expected to drive growth through 2020

Technavio report, renal denervation devices, 2015

August 23, 2016 — Technavio analysts forecast the global renal denervation market to grow at a compound annual growth rate (CAGR) of close to 12 percent during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global renal denervation market for 2016-2020. The demand for these devices is high. However, the market is growing slowly as clinical trials have failed to prove the safety and efficacy of many renal denervation devices. Technavio said the market will grow with the U.S. Food and Drug Administration (FDA) approval of Medtronic's SYMPLICITY HTN-4 renal denervation device after the completion of associated clinical study in February 2017.

Europe accounted for more than 57 percent of the market in 2015 due to the CE mark approval of a few of its renal denervation devices.

Technavio healthcare and life sciences analysts highlight the following three factors that are contributing to the growth of the global renal denervation market:

  • Widespread prevalence of hypertension;
  • Use of minimally-invasive procedures; and
  • Technological innovations to simplify renal denervation.

Widespread prevalence of hypertension

According to Barath Palada, a lead analyst at Technavio for medical devices research, “Unhealthy diet, stress and physical inactivity can lead to conditions such as hypertension, hypercholesterolemia, coronary artery disease and diabetes.”

Hypertension or high blood pressure can cause ischemia and stroke. With each passing year, the prevalence of hypertension is rising worldwide. In 2013, the Centers for Disease Control and Prevention (CDC) estimated that more than 30 percent of the global adult population had hypertension. Furthermore, in 2013, the organization estimated that 70 million adults in the United States had high blood pressure, accounting for one in every three adults in the country).

In 2015, the National Health Service estimated that about 500,000 people in the United Kingdom had drug-resistant hypertension. In many cases, blood pressures were higher than 140/90 mmHg and could not be managed even with three or more anti-hypertensives. These cases require the use of renal denervation devices to manage hypertension.

Use of minimally-invasive procedures

Physicians worldwide are emphasizing the use of minimally-invasive techniques in surgical procedures. A rise in the use of minimally-invasive, catheter-based endovascular procedure for managing hypertension has led to higher adoption of renal denervation devices. These devices are safe and effective, and reduce cardiometabolic risks. They also help reduce the length of hospital stays, as the procedure can be completed in about an hour, and people undergoing the procedure only need to stay in the hospital for six more hours or so. This reduces direct and indirect hospitalization costs.

Advances in the procedure have led to the development of a radiofrequency catheter-based approach for renal denervation. Radiofrequency therapy is applied to the endoluminal surface of renal arteries via an electrode located at the tip of the catheter. This type of renal denervation procedure causes no trauma and minimizes recovery time.

Technological innovations to simplify renal denervation

“Manufacturers are developing new catheter-based devices to simplify the technicality and shorten the duration of renal denervation procedures, which augurs well for the growth of the market,” said Barath.

  • St. Jude Medical's EnligHTN multi-electrode renal denervation system uses a basket catheter that contains four electrodes, one in each strut of the basket. These struts expand to establish contact between the electrodes and vessel walls. Each electrode activates separately for 90 seconds. The catheter is retrieved and rotated 45 degrees and a second set of ablations are made. Advances in technology have led to the development of intuitive touch-screen generators that reduce the duration of procedures. The device's features allow for simultaneous ablations, which reduces total ablation time from 24 minutes to four minutes.
  • Kona Medical’s Surround Sound Renal Denervation System delivers ablation energy to the posterior portion of a patient's body, which eliminates the need for catheterization. The device delivers ultrasound energy, which surrounds the artery and ablates the nerves located in the vicinity of the vessel.

Other vendor offerings include the Vessix renal denervation system from Boston Scientific Corp. and a percutaneous renal denervation system from ReCor Medical Inc.

For more information: www.technavio.com

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021